No Picture
Trading Ideas

EMERGING MARKETS-Mexican peso leads losses in Latam FX on U.S.-China trade standoff

* Trade deal may not be completed this year – sources * U.S. bill on Hong Kong human rights angers China * Mexican peso hits 6-week low (Updates prices; adds details, quote) By Medha Singh Nov 20 (Reuters) – Latin American assets moved lower on Wednesday as investors fled risky bets after a report that an initial trade deal between United States and China may not be completed this year. The tariff-sensitive Mexican peso hit its weakest level in six weeks against a steady dollar. …read more […]

No Picture
Trading Ideas

Quantum Computing Is (Almost) Here

Our pocket computers – you know them as smartphones – are small, fast and powerful thanks to the billions of bits and transistors packed into the chips they use.
Bits make up a computer’s memory and are the smallest building blocks of traditional computing. They can have one of two values, usually represented as either a 0 or a 1. Your phone has about 256 billion bits (or 32 gigabytes).
Transistors act as switches. Think of them as a roadway with a gate. A binary signal of 1 will tell the gate to allow the cars to flow down the roadway. A …read more […]

No Picture
Trading Ideas

UPDATE 1-Treasury yields drop on reports trade deal may not come this year

Treasury yields dropped on Wednesday on news a “phase one” U.S.-China trade deal may not be completed this year, according to Reuters sources. Negotiations to finalize a deal may extend into next year, trade experts and people close to the White House said, as Beijing presses for more extensive tariff rollbacks, and as the Trump administration counters with heightened demands of its own. Benchmark 10-year Treasury note yields were last down 5.6 basis points at 1.730%. …read more […]

No Picture
Trading Ideas

Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks

More than 500 biotech companies operate in the US, doing their part to make it the world’s hub for innovation. Only about 20 of them turn a profit, though, highlighting the dangers of the biotech sector. High overhead, long research terms, and the uncertainties of clinical testing and regulatory approval all weigh on them, making biotech at once the riskiest and most potentially profitable of the stock market’s segments.Enter Joseph Edelman. The hedge fund veteran started Perceptive Advisors back in 1999 with just $6 million, and his hedge has grown to hold over $5 billion in assets under management today. …read more […]

No Picture
Trading Ideas

UPDATE 1-Alnylam's rare genetic disorder drug gets early U.S. approval

Alnylam Pharmaceuticals Inc on Wednesday received an early U.S. approval for its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain. The drug, Givlaari, uses a mechanism known as RNA interference to target and “silence” specific genetic material, blocking the production of the protein that causes the disease called acute hepatic porphyria. …read more […]